8-K filed May 30, 2024, 7:59 PM ET ticker PHGE CIK 0001739174

regulatory confidence high sentiment negative materiality 0.78

BiomX receives NYSE American delisting notice for equity deficiency; interim CFO departs

BiomX Inc.

Stockholders' capital deficiency of $9.5M as of March 31, 2024; losses in five recent fiscal years.
Plan to regain compliance due June 22, 2024; final compliance deadline November 23, 2025.
Expects to reclassify $32.4M to equity via Series X Preferred conversion at July 2024 shareholder meeting.
Common stock to trade with '.BC' designation during cure period.
Interim CFO Avraham Gabay steps down May 31, 2024; CFO Marina Wolfson returns from maternity leave.

item 3.01 item 5.02

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-24-048030
form_type: 8-K
ticker: PHGE
cik: 0001739174
company_name: BiomX Inc.
filed_at: 2024-05-30T23:59:59+00:00
discovered_at: 2026-05-14T18:03:19.834241+00:00
generated_at: 2026-06-01T07:26:13.125165+00:00
sec_items: ["3.01", "5.02"]
event_type: regulatory
sentiment: negative
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-24-048030
json_url: https://secwatch.observer/filing/0001213900-24-048030.json
markdown_url: https://secwatch.observer/filing/0001213900-24-048030.md
text_url: https://secwatch.observer/filing/0001213900-24-048030.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1739174/000121390024048030/0001213900-24-048030-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1739174/000121390024048030/ea020712501-8k_biomxinc.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Marina Wolfson

Chief Financial Officer

PHGE · BiomX Inc.

Effective: 2024-05-31
Filed: May 30, 2024, 7:59 PM ET

following Ms. Marina Wolfson’s return from maternity leave

Departed (interim)

Avraham Gabay

Interim Chief Financial Officer

PHGE · BiomX Inc.

Effective: 2024-05-31
Successor: Marina Wolfson
Filed: May 30, 2024, 7:59 PM ET

Effective May 31, 2024, Mr. Avraham Gabay’s term as Interim Chief Financial Officer of the Company will conclude

Source-grounded claims

1e2f920599

Marina Wolfson was appointed as Chief Financial Officer at BiomX Inc..

following Ms. Marina Wolfson’s return from maternity leave

SEC 8-K Item 5.02 confidence 0.85 SEC evidence

70629b8d84

Avraham Gabay departed as Interim Chief Financial Officer at BiomX Inc..

Effective May 31, 2024, Mr. Avraham Gabay’s term as Interim Chief Financial Officer of the Company will conclude

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Comparable filings

TPST

Tempest Therapeutics warned by Nasdaq for low equity and board independence; two directors resign

Tempest Therapeutics, Inc. May 22, 2026, 5:28 PM ET regulatory Items 3.01, 5.02

same fact type: executive_change same SEC item: 3.01, 5.02 same event type: regulatory similar materiality

This filing

following Ms. Marina Wolfson’s return from maternity leave

Comparable filing

resignations of Mr. Michael Raab and Ms. Christine Pellizzari from the Board

Filing page SEC filing

GROO

Groovy dismisses auditor after SEC suspension, reduces authorized common 99.5%, two officers depart

GROOVY COMPANY, INC. May 28, 2026, 3:28 PM ET regulatory Items 4.01, 4.02, 5.03, 5.02, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: regulatory similar materiality

This filing

following Ms. Marina Wolfson’s return from maternity leave

Comparable filing

Effective May 1, 2026, Jeffrey D. Turner ceased to serve as the Company’s Chief Legal Officer.

Filing page SEC filing

OCFC

OceanFirst closes acquisition of Flushing Financial; issues shares to Warburg Pincus

OCEANFIRST FINANCIAL CORP June 1, 2026, 5:19 PM ET m_and_a Items 1.01, 3.02, 2.01, 2.03, 3.03, 5.02, 5.03, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 similar materiality

This filing

following Ms. Marina Wolfson’s return from maternity leave

Comparable filing

Todd Schell, designated by Warburg, was appointed to serve as a director of OceanFirst

Filing page SEC filing

CWBHF

Charlotte's Web appoints BAT GC to board, closes debt conversion & US$10M investment

Charlotte's Web Holdings, Inc. June 1, 2026, 5:13 PM ET other_material Items 5.02, 5.07, 8.01

same fact type: executive_change same SEC item: 5.02 similar materiality

This filing

following Ms. Marina Wolfson’s return from maternity leave

Comparable filing

Effective May 28, 2026 (the “Effective Date”), the board of directors of Charlotte’s Web Holdings, Inc. (the “Company”), appoint James Jeffery Raborn to the Company’s board of directors

Filing page SEC filing

CRVL

CorVel CEO Michael Combs to become Executive Chair; Sarah Scott appointed CEO and President effective July 1, 2026

CORVEL CORP June 1, 2026, 5:05 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 similar materiality

This filing

following Ms. Marina Wolfson’s return from maternity leave

Comparable filing

In connection with the leadership transition, the Board appointed Sarah Scott to serve as Chief Executive Officer and President of the Company, effective July 1, 2026.

Filing page SEC filing

TTD

The Trade Desk appoints Nate Olmstead as CFO effective July 9, 2026; interim CFO Davis resumes CAO role

Trade Desk, Inc. June 1, 2026, 4:35 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02 similar materiality

This filing

following Ms. Marina Wolfson’s return from maternity leave

Comparable filing

On June 1, 2026, The Trade Desk, Inc. (the “Company”) announced the appointment of Nate Olmstead, age 54, as the Company’s chief financial officer.

Filing page SEC filing

WST

West Pharmaceutical appoints Michel Lagarde as CEO; Green retires, Friel becomes Chair

WEST PHARMACEUTICAL SERVICES INC June 1, 2026, 4:32 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 similar materiality

This filing

following Ms. Marina Wolfson’s return from maternity leave

Comparable filing

As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.

Filing page SEC filing

VRRM

Verra Mobility CEO David Roberts steps down amid cost realignment; interim CEO Keyser appointed

VERRA MOBILITY Corp June 1, 2026, 4:29 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 similar materiality

This filing

following Ms. Marina Wolfson’s return from maternity leave

Comparable filing

On June 1, 2026, Verra Mobility Corporation (the “Company”) announced that the Board of Directors of the Company (the “Board”) approved the appointment of Jonathan Keyser as the Interim President and Chief Executive Officer of the Company, effective May 31, 2026.

Filing page SEC filing

Source: SEC EDGAR

accession 0001213900-24-048030

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.